Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin
Citations Over TimeTop 10% of 2015 papers
Abstract
New antibacterials are needed to tackle antibiotic-resistant bacteria. Type IIA topoisomerases (topo2As), the targets of fluoroquinolones, regulate DNA topology by creating transient double-strand DNA breaks. Here we report the first co-crystal structures of the antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cleaved DNA as the fluoroquinolone moxifloxacin. Unlike moxifloxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues rationalizing why QPT-1 can overcome fluoroquinolone resistance. Our data show etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agents act similarly. Analysis of multiple DNA gyrase co-crystal structures, including asymmetric cleavage complexes, led to a 'pair of swing-doors' hypothesis in which the movement of one DNA segment regulates cleavage and religation of the second DNA duplex. This mechanism can explain QPT-1's bacterial specificity. Structure-based strategies for developing topo2A antibacterials are suggested.
Related Papers
- → Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones(2000)233 cited
- → Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition(1994)162 cited
- → Biological and docking studies of topoisomerase IV inhibition by thiosemicarbazides(2010)34 cited
- → Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases(2012)15 cited
- → DNA Topoisomerases from Streptomyces and Their Inhibition by Some Antibiotic and Antitumoractive Agents(1991)1 cited